


**Amendments to the Abstract:**


The present invention relates to compounds of the formula (I):



or a pharmaceutically acceptable salt or solvate thereof, wherein:

~~A and B independently represent CH<sub>2</sub> or O, with the proviso that A and B are not simultaneously O;~~

Cy represents one of the following



optionally substituted by one to three groups selected from hydroxy, halogen,  $C_{1-6}$ alkyl,  $C_{1-6}$ alkoxy,  $C_{1-6}$ haloalkyl,  $C_{1-6}$ alkylamino and amino;

$R^1$  and  $R^2$  are independently selected from hydroxy, halogen,  $C_{1-6}$ alkyl,  $C_{1-6}$ alkoxy,  $C_{1-6}$ haloalkyl and  $C_{3-6}$ cycloalkyl;

n represents an integer from 0-4;

X is hydrogen, hydroxy, halogen or  $C_{1-6}$ alkoxy;

Y is oxy, thio, a 1-4 membered alkylene, a 2-4 membered alkylene ether, 2-4 membered alkylene thioether or an oxyethyleneoxy group, optionally substituted by 1 to 4 groups independently selected from hydroxy, halogen,  $C_{1-6}$ alkyl,  $C_{1-6}$ alkoxy and  $C_{1-6}$ haloalkyl;

Z is CH or N; and

p represents an integer from 0-5 when Z is CH or 0-4 when Z is N; when p represents 2 or more, two of  $R^2$ 's may be taken together with the carbon atoms to which they are attached to form a 5-8 membered cycloalkyl ring

to processes for the preparation of, intermediates used in the preparation of, compositions containing such compounds and the uses of such compounds as antagonists of the NMDA NR2B receptor.